 Connection
David Moreno to Treatment Outcome
This is a "connection" page, showing publications David Moreno has written about Treatment Outcome.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.164 |
|
|
|
-
Moreno DF, Oriol A, de la Rubia J, Hern?ndez MT, I?igo MB, Palomera L, de Arriba F, Gonz?lez Y, Teruel AI, Pardo JL, L?pez de la Gu?a A, Sampol A, R?os-Tamayo R, Sureda A, Guti?rrez NC, Calasanz MJ, Ramos MLM, Mateos MV, San Miguel J, Lahuerta JJ, Blad? J, Rosi?ol L. Is t(11;14) Always a Standard-Risk Cytogenetic Abnormality? Results From GEM05MENOS65 and GEM2012 PETHEMA/GEM Transplantation Trials. Clin Lymphoma Myeloma Leuk. 2025 Jul; 25(7):494-504.
Score: 0.085
-
Rodr?guez-Lobato LG, de Daniel A, Pereira A, Fern?ndez de Larrea C, Tovar N, Cibeira MT, Moreno DF, Mateos JM, Llobet N, Carcelero E, Mun?rriz D, Blad? J, Rosi?ol L. Attrition rates and treatment outcomes in multiple myeloma: real-world data over a 40-year period. Blood Cancer J. 2025 May 26; 15(1):103.
Score: 0.022
-
Zugasti I, Tormo-Ratera M, Oliver-Cald?s A, Soler-Perromat JC, Gonz?lez-Calle V, Moreno DF, Caba?as V, L?pez-Mu?oz N, Bartolom?-Solanas ?, Espa?ol-Rego M, Reguera-Ortega JL, Rosi?ol L, L?pez-Corral L, Tovar N, Rodr?guez-Lobato LG, Alvarez Perez RM, Varea S, Olesti E, Gomez-Grande A, Frutos L, Tamayo P, Juan M, Moraleda JM, Urbano-Ispizua ?, Gonz?lez-Navarro EA, Mart?nez-L?pez J, Mateos MV, Tom?s X, Setoain X, Fern?ndez de Larrea C. Clinical impact of [18F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myeloma. Blood Adv. 2025 Feb 11; 9(3):571-582.
Score: 0.021
-
Oliver-Caldes A, Espa?ol-Rego M, Zabaleta A, Gonz?lez-Calle V, Navarro-Vel?zquez S, Inog?s S, de Cerio AL, Caba?as V, L?pez-Mu?oz N, Rodr?guez-Otero P, Reguera JL, Moreno DF, Mart?nez-Cibrian N, L?pez-Corral L, P?rez-Amill L, Martin-Antonio B, Rosi?ol L, Cid J, Tovar N, S?ez-Pe?ataro J, L?pez-Parra M, Olesti E, Guill?n E, Varea S, Rodr?guez-Lobato LG, Battram AM, Gonz?lez MS, S?nchez-Salinas A, Gonz?lez-Navarro A, Ortiz-Maldonado V, Delgado J, Pr?sper F, Juan M, Mart?nez-L?pez J, Moraleda JM, Mateos MV, Urbano-Ispizua ?, Paiva B, Pascal M, Fern?ndez de Larrea C. Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma. Clin Cancer Res. 2024 May 15; 30(10):2085-2096.
Score: 0.020
-
Castillo JJ, Moreno DF, Arbelaez MI, Hunter ZR, Treon SP. CXCR4 mutations affect presentation and outcomes in patients with Waldenstr?m macroglobulinemia: A systematic review. Expert Rev Hematol. 2019 10; 12(10):873-881.
Score: 0.015
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|